title: Optimal therapy of primary ocular lymphoma.
authors.forename: P N
authors.initials: PN
authors.lastname: Plowman
authors.forename: A
authors.initials: A
authors.lastname: Taylor
authors.forename: A S N
authors.initials: AS
authors.lastname: Jackson
authors.forename: S
authors.initials: S
authors.lastname: Lightman
authors.forename: C
authors.initials: C
authors.lastname: Pavesio
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005134:Eye Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D007839:Functional Laterality; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D008727:Methotrexate / Q000008:administration & dosage; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D011241:Prednisone / Q000008:administration & dosage; D011878:Radiotherapy / Q000379:methods; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D002955:Leucovorin; D011241:Prednisone; D008727:Methotrexate